CN114222578B - 钙敏感受体激动剂化合物及其应用 - Google Patents

钙敏感受体激动剂化合物及其应用 Download PDF

Info

Publication number
CN114222578B
CN114222578B CN202080057062.XA CN202080057062A CN114222578B CN 114222578 B CN114222578 B CN 114222578B CN 202080057062 A CN202080057062 A CN 202080057062A CN 114222578 B CN114222578 B CN 114222578B
Authority
CN
China
Prior art keywords
calcium
compound
compounds
arg
amino acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN202080057062.XA
Other languages
English (en)
Chinese (zh)
Other versions
CN114222578A (zh
Inventor
吴方舟
张瑾
高菲
吴然
廖成
王雷
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Shanghai Hengrui Pharmaceutical Co Ltd
Original Assignee
Beijing Tuojie Biomedical Technology Co ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Beijing Tuojie Biomedical Technology Co ltd filed Critical Beijing Tuojie Biomedical Technology Co ltd
Priority to CN202410744948.1A priority Critical patent/CN118496313A/zh
Publication of CN114222578A publication Critical patent/CN114222578A/zh
Application granted granted Critical
Publication of CN114222578B publication Critical patent/CN114222578B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/542—Carboxylic acids, e.g. a fatty acid or an amino acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
    • A61P3/14—Drugs for disorders of the metabolism for electrolyte homeostasis for calcium homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/18—Drugs for disorders of the endocrine system of the parathyroid hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/18—Drugs for disorders of the endocrine system of the parathyroid hormones
    • A61P5/20—Drugs for disorders of the endocrine system of the parathyroid hormones for decreasing, blocking or antagonising the activity of PTH
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Endocrinology (AREA)
  • Diabetes (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Obesity (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Rheumatology (AREA)
  • Immunology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
CN202080057062.XA 2019-12-09 2020-12-08 钙敏感受体激动剂化合物及其应用 Active CN114222578B (zh)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN202410744948.1A CN118496313A (zh) 2019-12-09 2020-12-08 钙敏感受体激动剂化合物及其应用

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN2019112500881 2019-12-09
CN201911250088 2019-12-09
PCT/CN2020/134598 WO2021115272A1 (zh) 2019-12-09 2020-12-08 钙敏感受体激动剂化合物及其应用

Related Child Applications (1)

Application Number Title Priority Date Filing Date
CN202410744948.1A Division CN118496313A (zh) 2019-12-09 2020-12-08 钙敏感受体激动剂化合物及其应用

Publications (2)

Publication Number Publication Date
CN114222578A CN114222578A (zh) 2022-03-22
CN114222578B true CN114222578B (zh) 2024-06-25

Family

ID=76328843

Family Applications (2)

Application Number Title Priority Date Filing Date
CN202080057062.XA Active CN114222578B (zh) 2019-12-09 2020-12-08 钙敏感受体激动剂化合物及其应用
CN202410744948.1A Pending CN118496313A (zh) 2019-12-09 2020-12-08 钙敏感受体激动剂化合物及其应用

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN202410744948.1A Pending CN118496313A (zh) 2019-12-09 2020-12-08 钙敏感受体激动剂化合物及其应用

Country Status (11)

Country Link
US (1) US20230041996A1 (https=)
EP (1) EP4091623A4 (https=)
JP (1) JP7796013B2 (https=)
KR (1) KR20220110789A (https=)
CN (2) CN114222578B (https=)
AU (1) AU2020399030B2 (https=)
BR (1) BR112022011127A2 (https=)
CA (1) CA3159744A1 (https=)
MX (1) MX2022006892A (https=)
TW (1) TW202122410A (https=)
WO (1) WO2021115272A1 (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2022257940A1 (zh) * 2021-06-08 2022-12-15 北京拓界生物医药科技有限公司 钙敏感受体激动剂化合物的盐酸盐及药物组合物和其应用
EP4353248A4 (en) * 2021-06-08 2024-10-23 Beijing Tuo Jie Biopharmaceutical Co. Ltd. CALCIUM-SENSITIVE RECEPTOR AGONIST COMPOSITION AND APPLICATION THEREOF

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104168955A (zh) * 2011-11-10 2014-11-26 凯伊药品公司 拟钙剂及其使用方法
CN107674114A (zh) * 2009-07-29 2018-02-09 凯伊药品公司 用于降低甲状旁腺激素水平的治疗剂

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BRPI0407097A (pt) * 2003-04-23 2006-01-24 Japan Tobacco Inc Antagonista do casr
EP2643292A1 (en) * 2010-11-26 2013-10-02 Leo Pharma A/S Calcium-sensing receptor-active compounds
JP2014508103A (ja) * 2010-11-26 2014-04-03 レオ ファーマ アクティーゼルスカブ カルシウム感知受容体活性化合物
HRP20161566T1 (hr) * 2011-06-08 2017-02-24 Kai Pharmaceuticals, Inc. Terapijski agensi za reguliranje serumskog fosfora

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN107674114A (zh) * 2009-07-29 2018-02-09 凯伊药品公司 用于降低甲状旁腺激素水平的治疗剂
CN102711789B (zh) * 2009-07-29 2018-06-08 凯伊药品公司 用于降低甲状旁腺激素水平的治疗剂
CN104168955A (zh) * 2011-11-10 2014-11-26 凯伊药品公司 拟钙剂及其使用方法

Also Published As

Publication number Publication date
KR20220110789A (ko) 2022-08-09
AU2020399030B2 (en) 2026-04-09
CN118496313A (zh) 2024-08-16
AU2020399030A1 (en) 2022-06-23
CN114222578A (zh) 2022-03-22
TW202122410A (zh) 2021-06-16
BR112022011127A2 (pt) 2022-08-23
JP2023504904A (ja) 2023-02-07
EP4091623A1 (en) 2022-11-23
WO2021115272A1 (zh) 2021-06-17
EP4091623A4 (en) 2024-01-03
JP7796013B2 (ja) 2026-01-08
CA3159744A1 (en) 2021-06-17
MX2022006892A (es) 2022-10-07
US20230041996A1 (en) 2023-02-09

Similar Documents

Publication Publication Date Title
EP3398957B1 (en) Method for synthesizing etelcalcetide
AU2004251616A1 (en) Melanocortin receptor 4(MC4) agonists and their uses
CN114222578B (zh) 钙敏感受体激动剂化合物及其应用
CN116157413A (zh) 阿普拉鲁肽的制造、配制和给药
CN103242441A (zh) 一种齐考诺肽的固相合成方法
AU2009246059A1 (en) Peptides, peptidomimetics and derivatives thereof, the manufacturing thereof as well as their use for preparing a therapeutically and/or preventively active pharmaceutical composition
US20040122013A1 (en) Analogs of nocicettin
EP2943215A1 (en) Peptides for the treatment of cancer
JP2949129B2 (ja) 胃腸運動刺激活性を有するモチリン類似ポリペプチド
EP1997826A2 (en) Synthetic ligands for immunoglobulins and pharmaceutical compositions containing them
EP4137502A1 (en) Vipr2 antagonist peptide
WO2022257940A1 (zh) 钙敏感受体激动剂化合物的盐酸盐及药物组合物和其应用
HK40069562A (en) Calcium-sensing receptor agonist compound and application thereof
RU2827834C1 (ru) Соединение, представляющее собой агонист кальций-чувствительного рецептора, и его применение
HK40069562B (zh) 钙敏感受体激动剂化合物及其应用
CN117295510A (zh) 一种钙敏感受体激动剂的组合物及其应用
CN115057910A (zh) 补体活性调节剂，其制备方法及医药用途
CN121758557A (zh) 一种补体活性调节剂，其制备方法及医药用途
EP3341388A1 (en) Cyclic peptidomimetics, compositions containing them and their use in the treatment of diseases associated with angiogenesis
JP2026505364A (ja) Ｔｎｆ－アルファ結合剤およびそれを使用する方法
CN119912520A (zh) 一类神经肽ff受体肽类配体及其制备和应用
Li 2This work was supported in part by National Institutes
TW201233394A (en) TFPI inhibitors and methods of use

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 40069562

Country of ref document: HK

GR01 Patent grant
GR01 Patent grant
TR01 Transfer of patent right
TR01 Transfer of patent right

Effective date of registration: 20241024

Address after: 200245 No. 279, Wen Jing Road, Shanghai, Minhang District

Patentee after: SHANGHAI HENGRUI PHARMACEUTICAL Co.,Ltd.

Country or region after: China

Address before: 102206 floor 7, building 4, hospital 9, medical Road, Life Science Park, Changping District, Beijing

Patentee before: Beijing tuojie Biomedical Technology Co.,Ltd.

Country or region before: China